Summary

Your FTO result is the most studied obesity-associated genetic variant — the A allele increases appetite and reduces satiety signalling (not metabolic rate), producing ~1.5-3kg additional body weight per allele through eating behaviour rather than metabolism, but exercise and high-protein diets substantially attenuate the effect.

Genotype spectrum

TT (Normal appetite regulation)

Your appetite regulation system works at standard efficiency. You feel full when you've eaten enough and your caloric intake self-regulates reasonably well with adequate protein, fibre, and whole foods.

TA/AT (Intermediate — one risk allele)

You have mild appetite awareness value from knowing this. The effect of one allele is subtle — most people with TA genotype don't notice a difference from TT in daily life.

AA (Increased appetite — two risk alleles)

You know the specific mechanism driving your weight management challenge. This isn't metabolic rate.

Practical takeaway

For AA Carriers (Two Risk Alleles — Appetite-Focused Strategy)

Satiety-first eating — your core dietary framework:

1. High protein at every meal: 30g+ protein per meal (minimum). Protein is the most satiating macronutrient. It directly compensates for your reduced satiety signalling. Aim for >25% of total calories from protein.
• Breakfast: eggs, Greek yoghurt, protein smoothie
• Lunch/dinner: palm-sized protein portion minimum (chicken, fish, tofu, legumes)
• Snacks: protein-based (nuts, jerky, cheese, protein bar)

2. High fibre: 25-35g/day. Fibre slows gastric emptying, triggering more prolonged satiety hormone release.
• Vegetables with every meal
• Legumes (beans, lentils) 3-4x/week
• Whole grains over refined

3. Eat slowly: 20+ minutes per meal. Satiety hormones (PYY, GLP-1) take 15-20 minutes to reach the brain. Your satiety signalling is already quieter — rushing meals means the signal barely registers before you've overeaten.

4. Structured meals over grazing: 3-4 defined meals rather than continuous snacking. Each meal triggers a satiety hormone cascade; snacking produces smaller, less effective signals.

5. Water pre-loading: 500ml water 30 minutes before meals. RCT-supported caloric intake reduction (~75-90 kcal per meal in Dennis et al. 2010).

6. Environment management: Use smaller plates (10-inch instead of 12-inch). Don't eat from packages. Pre-portion snacks. Keep energy-dense foods out of sight. These aren't gimmicks — they're environmental controls that work WITH your neurobiology instead of relying on willpower against it.

Exercise — your single most powerful intervention:
• Physical activity attenuates your FTO risk by ~27-40% (Kilpeläinen 2011)
• Minimum 150 min/week moderate intensity. More is better for you specifically.
• Both aerobic and resistance training contribute. Resistance training builds metabolically active tissue AND acutely suppresses appetite.
• The exercise effect is independent of calories burned — it works through appetite regulation improvement.

What "working" looks like:
• Feeling satisfied (not just full) after meals
• Reduced between-meal snacking
• Less food-seeking behaviour when not hungry
• Gradual weight nor

Evidence detail

What This Gene Does

FTO encodes an RNA demethylase (m6A eraser) that modifies gene expression by removing methyl marks from messenger RNA. The gene is highly expressed in the hypothalamus — the brain region that controls appetite, satiety, and energy balance. FTO was the first gene identified by genome-wide association studies (GWAS) for obesity and remains the strongest common genetic predictor of BMI in the general population.

The rs9939609 variant (and tightly linked SNPs in the same region) sits in the first intron of FTO and affects its expression in the hypothalamus. The A allele (risk allele) is associated with increased FTO expression, which enhances appetite, reduces satiety after meals, and increases preference for energy-dense (high-fat, high-calorie) foods. Critically, FTO does NOT significantly affect metabolic rate or energy expenditure — the effect is almost entirely on the intake side of the energy balance equation.

Important mechanistic debate: Recent research (Smemo et al. 2014) suggests that the FTO intronic variants may actually exert their obesity effect through long-range regulation of the neighbouring IRX3 and IRX5 genes rather than FTO itself. The debate is unresolved, but the clinical implications are the same regardless of the causal gene: the variants in this region affect appetite and body weight through hypothalamic mechanisms.

Mechanism

FTO at the molecular level — the m6A connection:

FTO is an AlkB family RNA demethylase that removes N6-methyladenosine (m6A) marks from mRNA. m6A is the most abundant internal modification on messenger RNA and affects mRNA stability, splicing, and translation. By removing m6A marks, FTO alters the post-transcriptional regulation of target genes — effectively changing which proteins are made and how much.

In the hypothalamus, FTO targets include mRNAs involved in:
• Ghrelin signalling (hunger hormone pathway)
• Dopamine reward circuitry (food reward processing)
• Leptin sensitivity (satiety hormone response)
• Melanocortin pathway (appetite regulation — MC4R, POMC)

The rs9939609 A allele increases FTO expression in the hypothalamus. More FTO enzyme → more m6A removal from appetite-regulating mRNAs → altered appetite and reward signalling → increased caloric intake.

Why this affects appetite but not metabolic rate:

FTO's dominant expression site is the hypothalamus (appetite centre), not adipose tissue or muscle (metabolic centres). While FTO is expressed in many tissues, the obesity-relevant effect appears to be primarily central — it changes how the brain processes hunger and satiety signals, not how the body burns calories. This is consistent with the human studies (Cecil 2008, Karra 2013) showing appetite differences without metabolic rate differences.

The ghrelin-reward circuit:

Karra et al. (2013) showed that FTO AA carriers have:
1. Higher post-meal ghrelin levels (less suppression of the hunger hormone after eating)
2. Reduced hypothalamic satiety signalling (the brain doesn't "hear" fullness as loudly)
3. Enhanced nucleus accumbens response to food images (food is more rewarding)

This creates a specific behavioural pattern: AA carriers eat more per meal, compensate less after caloric preloads, and find energy-dense food more rewarding. It's not willpower — it's neurobiology.

Why exercise attenuates the effect:

Exercise independently:
1. Suppresses ghrelin (acutely)
2. Increases GLP-1 and PYY (satiety hormones)
3. Improves hypothalamic sensitivity to satiety signals
4. Reduces reward-driven eating behaviour
5. Improves insulin sensitivity (which affects appetite regulation)

These mechanisms directly counteract FTO's appetite-enhancing effects. Physically active AA carriers effectively "compensate" for the genetic satiety deficit through exercise-mediated satiety hormone improvements.

FTO Appetite

Summary

Genotype spectrum

Practical takeaway

Evidence detail

Sources (9)